The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation

Clinical and Experimental Immunology

Volumn 141, Issue 3, 2005, Pages 534-540

  Van Besouw, N M ^a   Zuijderwijk, J M ^a   Vaessen, L M B ^a   Balk, A H M M ^a   Maat, A P W M ^a   Van Der Meide, P H ^b   Weimar, W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Heart transplantation; Host versus graft disease; Human studies; T cells

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TETANUS TOXOID;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ADULT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INTERFERON TYPE II; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 23044487610     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02871.x     Document Type: Article

References (32)

1. Auchincloss H Jr, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol 1996; 8:681-7.
2. Matis LA, Sorger SB, McElligott DL, Fink PJ, Hedrick SM. The molecular basis of alloreactivity in antigen-specific, major histocompatibility complex-restricted T cell clones. Cell 1987; 51:59-69.
3. Lechler RI, Heaton T, Barber L, Bal V, Batchelor JR, Lombardi G. Molecular mimicry by major histocompatibility complex molecules and peptides accounts for some alloresponses. Immunol Lett 1992; 34:63-9.
4. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982; 156:1835-41.
5. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155:31-41.
6. Muluk SC, Clerici M, Via CS, Weir MR, Kimmel PL, Shearer GM. Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation 1991; 52:284-91.
7. van Besouw NM, Vaessen LMB, Knoop CJ et al. Evidence that cyclosporin A prevents clinical cardiac allograft rejection by blocking both direct and indirect antigen presentation pathways. Transplant Int 1996; 9 (Suppl. 1):S345-7.
8. Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998; 97:1257-63.
9. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001; 167:7199-206.
10. Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64:795-800.
11. Ciubotariu R, Liu Z, Colovai AI et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101:398-405.
12. SivaSai KS, Smith MA, Poindexter NJ et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67:1094-8.
13. Reznik SI, Jaramillo A, SivaSai KS et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001; 1:228-35.
14. Stanford RE, Ahmed S, Hodson M, Banner NR, Rose ML. A role for indirect allorecognition in lung transplant recipients with obliterative bronchiolitis. Am J Transplant 2003; 3:736-42.
15. Hornick PI, Mason PD, Baker RJ et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000; 101:2405-10.
16. Schulick RD, Weir MB, Miller MW, Cohen DJ, Bermas BL, Shearer GM. Longitudinal study of in vitro CD4+ T helper cell function in recently transplanted renal allograft patients undergoing tapering of their immunosuppressive drugs. Transplantation 1993; 56:590-6.
17. Liu Z, Sun YK, Xi YP et al. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993; 177:1643-50.
18. Liu Z, Colovai AI, Tugulea S et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Cli Invest 1996; 98:1150-7.
19. Molajoni ER, Cinti P, Orlandini A et al. Mechanism of liver allograft rejection: the indirect recognition pathway. Hum Immunol 1997; 53:57-63.
20. van Besouw NM, Vaessen LM, Daane CR et al. Peripheral monitoring of direct and indirect alloantigen presentation pathways in clinical heart transplant recipients. Transplantation 1996; 61:165-7.
21. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78:591-8.
22. Balk AH, Meeter K, Simoons ML et al. Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study. Transplant Int 1992; 5 (Suppl. 1):S476-9.
23. Billingham ME, Gary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587-93.
24. van Besouw NM, van der Mast BJ, de Kuiper P et al. Donor-specific T cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70:136-43.
25. van Besouw NM, Vaessen LMB, Zuijderwijk J et al. The frequency of IFN-γ producing cells reflects alloreactivity against minor histocompatibility antigens. Transplantation 2003; 75:1400-4.
26. Heeger PS, Greenspan NS, Kuhlenschmidt S et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163:2267-75.
27. Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, Heeger PS. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998; 66:219-24.
28. Gebauer BS, Hricik DE, Atallah A et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2:857-66.
29. Hricik DE, Rodriguez V, Riley J et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3:878-84.
30. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169:4667-73.
31. Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14:1643-51.
32. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 2002; 13:252-9.